- 3PBIOVIAN has expanded its sterility testing platform with isolator-based testing capabilities to support clinical and commercial manufacturing.
- The company said the investment strengthens its integrated CDMO offering by combining manufacturing and analytical testing under one roof.
3PBIOVIAN has expanded its sterility testing capabilities as part of its integrated CDMO offering supporting biopharmaceutical development and commercial manufacturing programs.
The company stated that the upgraded platform includes isolator-based sterility testing designed to provide higher sterility assurance and reduce contamination risks during analytical testing. According to 3PBIOVIAN, minimizing operator intervention and environmental exposure can help reduce test failures and inconclusive results while supporting shorter release timelines and operational efficiency.
The in-house sterility testing platform supports projects from development through clinical and commercial manufacturing stages. The company said the expanded capability enables customers to progress programs without relying on external testing laboratories, improving process control and operational continuity across the product lifecycle.
3PBIOVIAN noted that sterility testing has been part of its analytical operations for nearly three decades, supporting protein-based and viral products across its manufacturing network. The company said the capability is routinely used to support internal manufacturing activities at its two facilities.
According to 3PBIOVIAN, the recent investment combines existing analytical expertise with new facilities and equipment while integrating drug substance manufacturing, drug product manufacturing, and analytical testing into a single contract manufacturing workflow for biopharmaceutical customers.
